Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Schlumberger NV (SLB) Price & Performance

AstraZeneca plcTrade
Schlumberger NVTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Schlumberger NV — how do they compare? AstraZeneca plc trades at $158.79 (market cap $248.14B), while Schlumberger NV trades at $52.87 (market cap $79.67B). The key difference: AstraZeneca plc is far larger — about 3.1× Schlumberger NV's market cap, and Schlumberger NV pays the higher dividend (2.2%). Which is the better fit depends on your goals.

AZNSLB
Market Cap
$248.14B$79.67B
Sector
HealthEnergy
52-Week High
$209.48$58.01
52-Week Low
$147.06$31.72
Enterprise Value
$275.41B$88.40B
Dividend Yield
2.01%2.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.

The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.

Schlumberger NV

SLB trades at $52.96, down 0.45% on the day, with a bullish technical signal from moving averages and oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.55, and maintains a consensus analyst price target of $63.00. Revenue for 2025 was $35.71 billion, with a net income margin of 8.53%, though margins have softened from prior years. Recent news highlights growth in digital and offshore segments, offset by Middle East challenges.

The outlook for SLB is positive, driven by earnings beats and robust analyst support, but risks include regional volatility and margin pressure. Upside potential exists if digital and production gains accelerate, yet investors must weigh debt levels and geopolitical headwinds against the stock's current valuation near 52-week highs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Schlumberger NV

Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.

Read more on SLB